Resected periampullary adenocarcinoma: 5-year survivors and their 6- to 10-year follow-up.
about
Recent progress in pancreatic cancerCancer immunotherapy for pancreatic cancer utilizing α-gal epitope/natural anti-Gal antibody reactionAmpullary cancer: an overviewPancreatic Cancer: 80 Years of Surgery-Percentage and RepetitionsGatifloxacin induces S and G2-phase cell cycle arrest in pancreatic cancer cells via p21/p27/p53Whole blood DNA aberrant methylation in pancreatic adenocarcinoma shows association with the course of the disease: a pilot studyResectable adenocarcinomas in the pancreatic head: the retroperitoneal resection margin is an independent prognostic factor.Ampullary adenocarcinoma - differentiation matters.Predicting patient survival after pancreaticoduodenectomy for malignancy: histopathological criteria based on perineural infiltration and lymphovascular invasionWhat is the effect of age on pancreatic resection?Predictors of survival in periampullary cancers following pancreaticoduodenectomy.The Association between Survival and the Pathologic Features of Periampullary Tumors Varies over Time.Physician attitudes and treatment patterns for pancreatic cancer.Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma.Proteins associated with pancreatic cancer survival in patients with resectable pancreatic ductal adenocarcinoma.Preoperative computed tomography measurements of pancreatic steatosis and visceral fat: prognostic markers for dissemination and lethality of pancreatic adenocarcinoma.Resection benefits older adults with locoregional pancreatic cancer despite greater short-term morbidity and mortality.Pulmonary resection for isolated pancreatic adenocarcinoma metastasis: an analysis of outcomes and survivalVery Long-term Survival Following Resection for Pancreatic Cancer Is Not Explained by Commonly Mutated Genes: Results of Whole-Exome Sequencing AnalysisFactors affecting long-term survival after surgical resection of pancreatic ductal adenocarcinoma.Factors affecting survival in patients who underwent pancreaticoduodenectomy for periampullary cancers.Prognostic impact of immunohistochemical expression of CK7 and CK20 in curatively resected ampulla of Vater cancer.Tumors of ampulla of Vater: A case series and review of chemotherapy optionsSurvival Outcomes According to Adjuvant Treatment and Prognostic Factors Including Host Immune Markers in Patients with Curatively Resected Ampulla of Vater Cancer.Substaging Nodal Status in Ampullary Carcinomas has Significant Prognostic Value: Proposed Revised Staging Based on an Analysis of 313 Well-Characterized CasesHospital and medical care days in pancreatic cancerStromal galectin-1 expression is associated with long-term survival in resectable pancreatic ductal adenocarcinomaThe effect of depression on stage at diagnosis, treatment, and survival in pancreatic adenocarcinomaImproving Survival of Pancreatic Cancer. What Have We Learnt?Rare long-term survivors of pancreatic adenocarcinoma without curative resection.Nodal sampling in pancreaticoduodenectomy: does it change our management?Results of pancreatic surgery in the elderly: is age a barrier?Assessment of the effect of interval from presentation to surgery on outcome in patients with peri-ampullary malignancy.Long-term survival in patients with pancreatic ductal adenocarcinoma.Molecular targeted therapies for pancreatic cancer.Clinical calculator of conditional survival estimates for resected and unresected survivors of pancreatic cancerSurgical management of carcinoma of the head of pancreas: extended lymphadenectomy or modified en bloc resection?Outcomes following resection of pancreatic adenocarcinoma: 20-year experience at a single institution.Longterm survival after pancreaticoduodenectomy for periampullary adenocarcinomas.2564 resected periampullary adenocarcinomas at a single institution: trends over three decades.
P2860
Q24626346-7AE19270-E158-4490-949D-E04818A2137CQ26777542-1C8A36C0-5A77-460A-BDE3-FD977D75B754Q27023881-0511AFCF-0A77-479C-A733-C3C378585408Q28072182-DA4157A6-311C-4621-B854-26E22C23EF8CQ28484635-3A7FC7EE-7D27-4D00-8C13-87F5FDDA4B96Q28729757-3DD3A2DD-DD0D-4B14-B021-21A292155AA8Q33314616-5B3F8724-4868-44AC-8258-3BEEB7D6FBEBQ33365424-5FFD3517-4C43-4B45-AF48-65C49FDC985EQ33679644-39C55E1B-E526-4ED8-B1D4-F933393CE982Q33791889-E57D9ED3-AEAD-43BF-939A-14A7B30A3D66Q33819380-5E63B3F3-125E-485C-B587-06ADAEDD83C7Q33914755-3B3EA088-E3BE-4D24-A0F1-C4DB1FF36B25Q34626379-5F67FDC3-57C8-476A-BD39-F9181F62339DQ34732306-B3102FC2-3E2B-43DF-B14C-A21A6F82972FQ34797866-710235D7-1A58-44E6-A8A5-2D4D99A17303Q35010225-1882A822-6C9E-42FE-A143-CB744935FA7EQ35166339-7BEFC202-3387-4809-AC70-996BF05F80F1Q35177885-5064D217-51E2-40DF-BA34-D9019EAF6386Q35463399-E99BF889-7BCA-47E3-890C-FDD71D06ED64Q35627199-DB924A26-FE0E-4378-9EA4-D501680B2DC4Q35799243-74F2AA01-4AC3-45A6-8F7D-42148CB43C95Q35851586-D16D33B1-6F4A-4FC2-B1BF-B00647F4E919Q35854505-E1B4FDFC-1117-4519-94C8-E5807B11E235Q35956259-B063EA91-9109-48BC-8098-CA27D030F6CDQ36073271-401C4622-AE99-41C8-AAE2-F2D31095318EQ36124007-5201D041-1FF3-4FBC-9289-61ED33221D87Q36149299-C6AB02CA-3E20-4474-8F75-6DF5F8CF5967Q36300227-A14C3D87-DD5C-4D03-A69D-AAB434D86D8AQ36400047-5C198FBD-5081-41AE-81E6-CAF74DA34C1CQ36401628-BE93121E-FDE7-4B4E-B5E6-17A9FD6B4ED7Q36408353-A4BB65F6-1F6C-4016-BB94-B2109D2AD6A1Q36498469-59AFB60A-40C8-4EE1-A45D-473B5BB97519Q36747409-F44C5148-01BE-40AD-B67F-BC93B937FF43Q36869288-3648B5E3-30DB-412F-BA9A-DCB5E288BE00Q36944441-5DB4DC24-1627-4482-844F-857C1B2E550FQ37086658-A7126BD1-7AED-4926-B664-11D7B448056CQ37119088-B96C845D-918F-4DF6-9AC4-674668EC628CQ37277964-BC230119-0CF5-4B4A-8098-7D3E23958625Q37350307-92930367-E782-4453-AA63-164EA9ADDEA9Q37480871-48C7322A-1F8E-4C1E-8E12-96747288143F
P2860
Resected periampullary adenocarcinoma: 5-year survivors and their 6- to 10-year follow-up.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Resected periampullary adenoca ...... their 6- to 10-year follow-up.
@en
Resected periampullary adenoca ...... their 6- to 10-year follow-up.
@nl
type
label
Resected periampullary adenoca ...... their 6- to 10-year follow-up.
@en
Resected periampullary adenoca ...... their 6- to 10-year follow-up.
@nl
prefLabel
Resected periampullary adenoca ...... their 6- to 10-year follow-up.
@en
Resected periampullary adenoca ...... their 6- to 10-year follow-up.
@nl
P2093
P1433
P1476
Resected periampullary adenoca ...... their 6- to 10-year follow-up.
@en
P2093
Charles J Yeo
David Chang
John L Cameron
Jordan M Winter
Keith D Lillemoe
Kurtis A Campbell
Taylor S Riall
P304
P356
10.1016/J.SURG.2006.04.006
P407
P577
2006-08-28T00:00:00Z